Xiao Feng

Xiao Feng has extensive work experience in the biopharmaceutical industry. Starting in 1993, they worked as a Research Scientist at Yes Biotech Laboratories, Ltd. In 2000, they transitioned to Molecular Staging, Inc. as a Research Scientist until 2001. From 2001 to 2013, Xiao Feng held the role of Principal Scientist at Johnson & Johnson. In 2013, they joined Alkermes as a Principal Scientist until 2017. From 2017 to 2019, Xiao Feng worked as the Senior Director, Head of Toxicology/DMPK at Corbus Pharmaceuticals. They then moved to Boston Pharmaceuticals in 2019 as the Executive Director, Head of Toxicology & DMPK. Currently, Xiao Feng is with Zenas BioPharma, starting as the Executive Director, Head of Preclinical DMPK and Toxicology in 2021 and later becoming the Vice President, Head of Nonclinical Development in 2022.

Xiao Feng has a diverse education history. Xiao obtained a Ph.D. in Cell Biology from Duke University, completing their studies between 1995 and 1998. Prior to that, they earned an M.S. in Genetics from Fudan University, where they studied from 1986 to 1989. Xiao Feng also holds a Bachelor's degree in Biology from Fudan University, which they obtained between 1982 and 1986.

Additionally, they pursued further education and obtained a Master of Business Administration (MBA) from Babson College, attending from 2013 to 2014. Furthermore, Xiao Feng has obtained certifications from the American Board of Toxicology, Inc., namely the Diplomate of the American Board of Toxicology (DABT). It is unclear when exactly they received this certification.